Significant reduction in vertebral fracture risk: Evidence for the efficacy of daily and intermittent ibandronate from a large phase III study

被引：0
|
作者：
Christiansen, C
Chesnut, CH
Delmas, PD
Skag, A
Recker, RR
Stakkestad, JA
Hoiseth, A
Felsenberg, D
Gilbride, J
Schimmer, RC
机构：
[1] Ctr Clin & Basic Res, Ballerup, Denmark
[2] Univ Washington, Seattle, WA 98195 USA
[3] Univ Lyon 1, F-69365 Lyon, France
[4] INSERM, Res Unit 403, Lyon, France
[5] Ctr Clin Trials, Bergen, Norway
[6] Creighton Univ, Omaha, NE 68178 USA
[7] CECOR AS Haugesund, Oslo, Norway
[8] Sentrum Rontgen Inst AS, Oslo, Norway
[9] Univ Klinikum Benjamin Franklin, Berlin, Germany
[10] F Hoffmann La Roche Ltd, Basel, Switzerland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2003年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：94 / 95
页数：2
相关论文
共 43 条
  • [11] Non-vertebral fracture benefit from oral ibandronate administered daily or with a unique drug-free interval: Results from a pivotal phase III study in postmenopausal osteoporosis (PMO).
    Recker, R
    Stakkestad, JA
    Weber, T
    Cohen, S
    Delmas, P
    Schimmer, R
    Mahoney, P
    Kilbride, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S134 - S134
  • [12] Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study
    Ringe, JD
    Dorst, A
    Faber, H
    Ibach, K
    Sorenson, F
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 (10) : 801 - 807
  • [13] Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study
    J. D. Ringe
    A. Dorst
    H. Faber
    K. Ibach
    F. Sorenson
    Osteoporosis International, 2003, 14 : 801 - 807
  • [14] Changes in bone mineral density as a predictor of vertebral fracture efficacy with lbandronate: Results from a phase III fracture study.
    Wasnich, R
    Miller, PD
    Chesnut, CH
    Huss, H
    Wilson, K
    Schimmer, RC
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S160 - S160
  • [15] Oral daily and intermittent ibandronate provide significant and sustained reductions in height loss in postmenopausal osteoporosis: Results from the bone study
    Delmas, PD
    Hoiseth, A
    Gilbride, J
    Schimmer, RC
    Chesnut, CH
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S75 - S75
  • [16] Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: Results from a pivotal phase III study
    Delmas, P
    Recker, R
    Stakkestad, JA
    Chestnut, C
    Hoiseth, A
    Weichselberger, A
    Huss, H
    von Stein, T
    Schimmer, R
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S15 - S15
  • [17] Oral ibandronate is equally well tolerated in elderly and younger patients: Results from a phase III fracture study
    Felsenberg, D
    Hoiseth, A
    Skag, A
    Leishman, B
    Schimmer, RC
    Ettinger, MP
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S71 - S71
  • [18] CLINICAL EFFICACY OF MONTHLY IV IBANDRONATE VS. DAILY ORAL RISEDRONATE IN PATIENTS WITH PRIMARY OSTEOPOROSIS: THE PHASE III MOVER STUDY
    Ito, Masako
    Nakamura, Toshitaka
    Nakano, Tetsuo
    Hagino, Hiroshi
    Hashimoto, Junko
    Tobinai, Masato
    Mizunuma, Hideki
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 : S224 - S225
  • [19] Fracture Risk with Once-Monthly Oral Ibandronate Compared with Weekly Bisphosphonates: Primary and Sensitivity Analyses from the eValuation of IBandronate Efficacy (VIBE) Database Fracture Study.
    Harris, S. T.
    Blumentals, W. A.
    Poston, S. A.
    Silverman, S. L.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S346 - S346
  • [20] Oral ibandronate reduces non-vertebral fracture risk in postmenopausal osteoporosis: Results from a sub-analysis of a pivotal study
    Stakkestad, Jacob A.
    Emkey, Ronald
    Neate, Colin
    Chesnut, Charles H.
    BONE, 2008, 42 : S86 - S86
12345